Bullish Case: GMED sits at $75.65 with call volume running 90% above puts, bullish risk skew +12%, and Helium's PDF peaking at 77.5 with meaningful mass to 80-85 versus the market's flatter, put-heavier curve. Q2 showed 6% revenue growth (9% ex-Nevro), US Spine +7%, International +14%, and an EPS guidance beat. Backwardated near-term IV (~44-48% ATM) implies premium is rich relative to the last 90 days' flat price action; if $75 holds and IV mean-reverts, a drift back toward $80-88 into year-end is the highest-density path.

Bearish Case: The stock is down 13% in sixty days, broke the $78 support I flagged repeatedly, and the term structure remains backwardated with steep lower-strike put wings (55P IV 96%, 60P 79%) — the market still prices tail risk. The Nevro spinal cord stimulator MDL (transferred to N.D. Cal., Oct 5) adds unquantified litigation drag, P/B of 4.1 offers little cushion, and Helium's return surface retains heavy negative mass at longer windows. A close below $72.5 with rising SPY IV would shift odds decisively lower.

Potential Outcomes:

1. 38% $72–$80 consolidation into Feb '27: Helium PDF peak 75–77.5 holds; falsified by close <$69.
2. 24% Reclaim $80–$88: call flow + IV mean-reversion; trigger: close >$78 on falling put IV.
3. 20% $65–$72: $72.5 breaks, wings steepen, MDL discovery headlines.
4. 12% >$90: catalyst/M&A; Dec'27+ call flow hints.
5. 6% <$60 tail: litigation/regulatory shock; deep put IV >100%.

October 20, 2026